A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

This is a dose and schedule finding study of AMG 531 designed to assess the activity of AMG 531 to reduce the rate of clinically significant bleeding and blood transfusions in subjects with myelodysplastic syndrome (MDS) receiving lenalidomide. Subjects with MDS that are planned to receive at least four cycles of lenalidomide for treatment of their disease are appropriate to screen for this study.

All subjects meeting the eligibility criteria will receive lenalidomide 10 mg capsule by mouth daily every day of each 28-day cycle. Subjects will receive AMG 531 or placebo once a week by subcutaneous injection for 16 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelodysplastic Syndromes Blood Platelet Disorders Bone Marrow Diseases Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Thrombocytopenia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO) classification
Low or Intermediate-1 risk category MDS using the IPSS
Planned to receive lenalidomide 10 mg capsule by mouth daily for all 28 days of each cycle for at least 4 cycles
Eastern Cooperative Oncology (ECOG) performance status of 0-2
Subjects must be at least 18 years of age or older

Exclusion criteria

Prior exposure to >3 cycles of lenalidomide
Exposure to lenalidomide within the last 30 days
Prior history of leukemia or aplastic anemia
Prior history of stem cell transplantation
Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for 3 years before randomization
Active or uncontrolled infections
Unstable angina, congestive heart failure [NYHA > class II], uncontrolled hypertension [diastolic > 100 mmHg], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past year
History of venous thrombosis in the past year
Received IL-11 within 4 weeks of screening
Less than 4 weeks since receipt of any investigational drug or device
Have previously received any other thrombopoietic growth factor
Pregnant or breast feeding
Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator
Known hypersensitivity to any recombinant E coli-derived product

Treatment and study plan

AMG 531

Biological

AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.

Placebo

Drug

Subjects in the control group will receive placebo via subcutaneous injection.

Primary outcomes

Occurrence of a Clinically Significant Thrombocytopenic Event

Time frame: Treatment period through interim follow-up visit (up to 16 weeks)

Occurrence of one or more clinically significant thrombocytopenic events, defined as either Common Terminology Criteria for Adverse Events (CTCAE) v. 3 grade 3 or 4 thrombocytopenia starting from week 3 of cycle 1 or receipt of platelet transfusions starting from week 1 of cycle 1 and continuing through the end of treatment visit.

Secondary outcomes

Lenalidomide Dose Reduction and Delay Due to Thrombocytopenia

Time frame: Treatment period (up to 16 weeks)

Occurrence of lenalidomide dose reduction and delay due to thrombocytopenia
Achieving an Overall Response (Complete Response (CR) or Partial Response (PR)) Determined by the Investigator Based on Modified International Working Group 2006 Response Criteria Guidelines

Time frame: Treatment period and post-treatment follow-up (up to 21 weeks)

CR = decrease in bone marrow blast (≤5%) and improvement in peripheral blood counts (Hgb ≥ 11 g/dL, platelets ≥ 100x10^9/L, neutrophils ≥ 1x10^9/L, peripheral blasts=0%). PR = improvement in peripheral blood counts plus a decrease in bone marrow blasts ≥50% but not ≤5, or decrease in International Prognostic Scoring System score.
Platelet Transfusion

Time frame: Treatment period (up to 16 weeks)

Occurrence of one or more platelet transfusions during the treatment period

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide.

Important dates

Study start: 2006
Primary completion: 2009
Study completion: 2010
First posted: Jan 5, 2007
Registry last updated: Jan 24, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed